Chi Podcasts

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases